Neupro
(Rotigotine)ApprovedSmall molecule
UCBRotigotine is used to treat Parkinson's disease and restless legs syndrome by helping to restore balance of certain chemicals in the brain that control movement and sensations.[2] Neupro is currently approved and in use across 6 indications[4].[1]
Neupro is one of 168 small molecule programs targeting Restless Legs Syndrome. It is currently in Approved.
6
Indications
60
Total Trials
0
Active Trials
167
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
91 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Neupro
UCBApproved
Kisunla
Eli LillyApproved
Dayvigo
EisaiApproved
Estrace
Novo NordiskApproved
Avandia
Jazz PharmaceuticalsApproved
Evista
Eli LillyApproved
Niacor
AbbVieApproved
Depakote
AbbVieApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Rexulti
OtsukaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Restless Legs Syndrome13 trials
Show 10 more trials
Parkinson's Disease11 trials
Show 8 more trials
Idiopathic Parkinson's Disease8 trials
Show 5 more trials
Liver3 trials
Itching2 trials
Switching From Oral Dopamine Agonists to Rotigotine
Completed·—·Phase 4·NCT01976871·21 enrolled
18 more indications
ESS2 trials
Treatment2 trials
Apathy1 trial
Tics1 trial
Restless Leg Syndrome1 trial
Parkinson1 trial
Fibromyalgia1 trial
Female1 trial
Parkinson's Disease (PD)1 trial
Gastrointestinal Dysfunction1 trial
Trial1 trial
Sleep Disorder1 trial
Regulatory
FDA Approval Timeline[5]
Apr 2, 2012
NEUPRO
NDA NDA021829
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Neupro drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Rotigotine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Neupro. U.S. Food & Drug Administration.
- [7]